Effects of anti‐IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real‐life multicentre study (BIONIGE) [PDF]
Clinical and Translational Allergy, 2022 Background Mepolizumab and benralizumab are clinically effective biological treatments for severe eosinophilic asthmatic patients by hampering eosinophilic inflammation. The effects of these compound on the immunoglobulin (Ig)E T2 component are virtually
Marco Contoli +13 more
doaj +2 more sources
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study [PDF]
Respiratory Research, 2023 Background The efficacy of benralizumab has been broadly demonstrated in severe eosinophilic asthma (SEA), but only few real-life studies evaluated its long-term effects.
Alessandra Vultaggio +22 more
doaj +2 more sources
Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis [PDF]
Frontiers in Allergy, 2022 BackgroundSevere eosinophilic asthma (SEA) in the presence of chronic rhinosinusitis with nasal polyps (CRSwNP) indicates the presence of a more extensive eosinophilic inflammation.
Maria D'Amato +27 more
doaj +6 more sources
Long-term effectiveness and safety of benralizumab in EGPA: a 3-year single-center experience [PDF]
Annals of MedicineObjectives Benralizumab emerged as a promising treatment option for eosinophilic granulomatosis with polyangiitis (EGPA). This study assessed the long-term effectiveness and safety of benralizumab in patients with severe asthma and relapsing-refractory ...
Federica Davanzo +10 more
doaj +2 more sources
Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma [PDF]
BMJ Open Respiratory Research, 2023 Introduction Eosinophil depletion with benralizumab reduces exacerbations and improves disease control and FEV1 in patients with severe eosinophilic asthma. However, few studies have investigated the effect of biologics on small airways dysfunction (SAD)
Brian J Lipworth, Rory Chan
doaj +4 more sources
Novel Humanized Mouse Model for Steroid‐Resistant Asthma [PDF]
AllergyAllergy, Volume 81, Issue 1, Page 256-259, January 2026.
Shiho Yamada +9 more
wiley +2 more sources
Discontinuation of Oral Glucocorticoids and Achievement of Remission in Patients With Eosinophilic Granulomatosis With Polyangiitis Treated With Benralizumab or Mepolizumab [PDF]
ACR Open RheumatologyObjective In the phase 3 head‐to‐head MANDARA study (NCT04157348), benralizumab demonstrated noninferiority to mepolizumab in inducing remission (defined as Birmingham Vasculitis Activity Score [BVAS] of 0 and oral glucocorticoid [OGC] dosage ≤4 mg/day ...
Michael E. Wechsler +9 more
doaj +2 more sources
Benralizumab Depletes IL‐5Rα‐Bearing Cells in Skin Lesions of Patients With Atopic Dermatitis [PDF]
Clinical and Translational AllergyBackground Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by tissue eosinophilia and itch. We evaluated the effect of eosinophil depletion with benralizumab on markers of inflammation in the skin of patients with AD.
Christiane E. Whetstone +15 more
doaj +2 more sources
Frontiers in Pharmacology, 2022 Two types of interleukin (IL)-5 antibody biologics, anti-IL-5 antibodies (mepolizumab) and anti-IL-5α receptor antibodies (benralizumab), are indicated for severe asthma.
Yasuhiko Koga +7 more
doaj +1 more source
Biomolecules, 2023 Benralizumab treatment reduces exacerbations and improves symptom control and quality of life in patients with severe eosinophilic asthma. However, the determination of biomarkers that predict therapeutic effectiveness is required for precision medicine.
Yuuki Sandhu +17 more
doaj +1 more source